State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET

被引:39
作者
Carlier, Thomas [1 ,2 ]
Bailly, Clement [1 ]
机构
[1] Univ Hosp, Nucl Med Dept, Pl Alexis Ricordeau, F-44093 Nantes, France
[2] CNRS, CRCNA, INSERM, UMR 6299,U892, Nantes, France
来源
FRONTIERS IN MEDICINE | 2015年 / 2卷
关键词
nuclearmedicine; PET; follow-up; oncology; quantification;
D O I
10.3389/fmed.2015.00018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
F-18-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) is an important tool in oncology. Its use has greatly progressed from initial diagnosis to staging and patient monitoring. The information derived from F-18-FDG-PET allowed the development of a wide range of PET quantitative analysis techniques ranging from simple semi-quantitative methods like the standardized uptake value (SUV) to "high order metrics" that require a segmentation step and additional image processing. In this review, these methods are discussed, focusing particularly on the available methodologies that can be used in clinical trials as well as their current applications in international consensus for PET interpretation in lymphoma and solid tumors.
引用
收藏
页数:12
相关论文
共 126 条
  • [1] A Systematic Review of the Factors Affecting Accuracy of SUV Measurements
    Adams, Michael C.
    Turkington, Timothy G.
    Wilson, Joshua M.
    Wong, Terence Z.
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2010, 195 (02) : 310 - 320
  • [2] Measuring Response with FDG-PET: Methodological Aspects
    Allen-Auerbach, Martin
    Weber, Wolfgang A.
    [J]. ONCOLOGIST, 2009, 14 (04) : 369 - 377
  • [3] Predicting Future Morphological Changes of Lesions from Radiotracer Uptake in 18F-FDG-PET Images
    Bagci, Ulas
    Yao, Jianhua
    Miller-Jaster, Kirsten
    Chen, Xinjian
    Mollura, Daniel J.
    [J]. PLOS ONE, 2013, 8 (02):
  • [4] Tumor Quantification in Clinical Positron Emission Tomography
    Bai, Bing
    Bading, James
    Conti, Peter S.
    [J]. THERANOSTICS, 2013, 3 (10): : 787 - 801
  • [5] Improving PET spatial resolution and detectability for prostate cancer imaging
    Bal, H.
    Guerin, L.
    Casey, M. E.
    Conti, M.
    Eriksson, L.
    Michel, C.
    Fanti, S.
    Pettinato, C.
    Adler, S.
    Choyke, P.
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2014, 59 (15) : 4411 - 4426
  • [6] Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
    Barrington, Sally F.
    Mikhaeel, N. George
    Kostakoglu, Lale
    Meignan, Michel
    Hutchings, Martin
    Mueeller, Stefan P.
    Schwartz, Lawrence H.
    Zucca, Emanuele
    Fisher, Richard I.
    Trotman, Judith
    Hoekstra, Otto S.
    Hicks, Rodney J.
    O'Doherty, Michael J.
    Hustinx, Roland
    Biggi, Alberto
    Cheson, Bruce D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) : 3048 - +
  • [7] FDG PET/CT methodology for evaluation of treatment response in lymphoma: from "graded visual analysis" and "semiquantitative SUVmax" to global disease burden assessment
    Basu, Sandip
    Zaidi, Habib
    Salavati, Ali
    Hess, Soren
    Carlsen, Poul Flemming Hoilund
    Alavi, Abass
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (11) : 2158 - 2160
  • [8] A novel fuzzy C-means algorithm for unsupervised heterogeneous tumor quantification in PET
    Belhassen, Saoussen
    Zaidi, Habib
    [J]. MEDICAL PHYSICS, 2010, 37 (03) : 1309 - 1324
  • [9] Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET
    Berkowitz, Arnold
    Basu, Sandip
    Srinivas, Shyam
    Sankaran, Shrinkanthan
    Schuster, Stephen
    Alavi, Abass
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2008, 29 (06) : 521 - 526
  • [10] Variations in Clinical PET/CT Operations: Results of an International Survey of Active PET/CT Users
    Beyer, Thomas
    Czernin, Johannes
    Freudenberg, Lutz S.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (02) : 303 - 310